| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
(±)-Naproxen-d3 targets the same biological targets as its non-deuterated counterpart, naproxen. Naproxen is a non-selective inhibitor of cyclooxygenase (COX) enzymes, COX-1 and COX-2. By inhibiting these enzymes, it reduces the synthesis of prostaglandins, which are mediators of pain, inflammation, and fever.
|
|---|---|
| ln Vitro |
(±)-Naproxen-d3 is a deuterium-labeled form of racemic naproxen, a nonsteroidal anti-inflammatory drug (NSAID). It inhibits COX-1 and COX-2 enzymes with similar potency to unlabeled naproxen. Its in vitro activity can be assessed by measuring the inhibition of prostaglandin synthesis in cell-based assays or by its ability to inhibit purified COX enzymes.
|
| ln Vivo |
(±)-Naproxen-d3 exhibits the same in vivo pharmacological activity as naproxen. It is an NSAID used to treat pain, inflammation, and fever. As a deuterated analog, it is primarily used as an internal standard for the quantification of naproxen in biological samples. The compound is not intended for therapeutic use as a labeled standard.
|
| Enzyme Assay |
The binding affinity of (±)-Naproxen-d3 to COX-1 and COX-2 can be assessed using enzyme inhibition assays. Purified COX enzymes are incubated with arachidonic acid and varying concentrations of the compound. The production of prostaglandins is measured, and the IC50 is determined. The compound's performance as an internal standard is assessed by its ability to provide accurate and precise quantification of naproxen by LC-MS/MS.
|
| Cell Assay |
(±)-Naproxen-d3 is used as an internal standard for the quantification of naproxen in cell-based studies. Cells are treated with naproxen, and the labeled compound is added to samples for LC-MS/MS analysis to accurately measure drug concentrations. The compound itself is not used to treat cells for a pharmacological effect in this context.
|
| Animal Protocol |
(±)-Naproxen-d3 is used as an internal standard in pharmacokinetic studies of naproxen in animal models. Animals are administered naproxen, and the labeled compound is added to biological samples for LC-MS/MS analysis to accurately quantify drug levels. The compound itself is not administered to animals as a therapeutic agent.
|
| ADME/Pharmacokinetics |
(±)-Naproxen-d3 has a molecular weight of 233.28 g/mol and a molecular formula of C14H11D3O3. It is a solid that is soluble in DMSO. The compound should be stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years.
|
| Toxicity/Toxicokinetics |
Toxicological data for (±)-Naproxen-d3 are not extensively detailed, as it is a research compound. It is not intended for human or veterinary use. Standard laboratory safety precautions, including the use of personal protective equipment (PPE), should be followed when handling the compound.
|
| References | |
| Additional Infomation |
(±)-Naproxen-d3 is a research-grade compound used as an internal standard for the quantification of naproxen by LC-MS/MS. Its deuterium labeling enables accurate and precise measurement of naproxen in biological samples for pharmacokinetic and bioequivalence studies. The compound is not approved for therapeutic use and is strictly for laboratory research.
|
| Molecular Formula |
C14H11D3O3
|
|---|---|
| Molecular Weight |
233.28
|
| Exact Mass |
233.113
|
| CAS # |
958293-79-3
|
| Related CAS # |
(±)-Naproxen;23981-80-8
|
| PubChem CID |
59015003
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.036
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
277
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([2H])([2H])[2H])C1C=CC2C=C(C=CC=2C=1)C(C(=O)O)C
|
| InChi Key |
CMWTZPSULFXXJA-BMSJAHLVSA-N
|
| InChi Code |
InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/i2D3
|
| Chemical Name |
2-[6-(trideuteriomethoxy)naphthalen-2-yl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2867 mL | 21.4335 mL | 42.8669 mL | |
| 5 mM | 0.8573 mL | 4.2867 mL | 8.5734 mL | |
| 10 mM | 0.4287 mL | 2.1433 mL | 4.2867 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
